HER-2/neu expression in prostate cancer

High level of expression associated with exposure to hormone therapy and androgen independent disease

Yan Shi, Frank H. Brands, Sunanda Chatterjee, An Chen Feng, Susan Groshen, Jörg Schewe, Gary Lieskovsky, Richard J Cote

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Purpose: HER-2/neu is a proto-oncogene that encodes a transmembrane receptor belonging to the family of epidermal growth factor receptors. Increasing evidences indicates that HER-2/neu may contribute to hormone resistance in prostate cancer. We investigated HER-2/neu expression in primary, androgen dependent and advanced androgen independent prostate cancer, and its potential value as a marker of disease progression. Materials and Methods: Immunohistochemical testing was performed to investigate HER-2/ neu expression in 81 patients with prostate cancer, including 31 with pathological stage C disease treated with radical prostatectomy without preoperative androgen ablation therapy (untreated group), 30 with pathological stage C disease treated before surgery with androgen ablation therapy (treated group) and 20 with advanced androgen independent prostate cancer (androgen independent group). Tumors were classified based on the percent of tumor cells showing HER-2/neu membrane immunoreactivity as low (50% or less) and high (50% or greater) expression. Results: Of the 31 prostate tumors in the untreated group 9 (29%) showed high HER-2/neu expression versus 15 of 30 (50%) in the treated and 17 of 20 (85%) in the androgen independent groups. The difference in HER-2/neu expression was significant in the untreated and androgen independent (p <0.001) and in the treated and androgen independent (p = 0.016) groups. There was a significant association of Gleason score with HER-2/neu expression in the untreated group (p = 0.038) but not in the treated group. No association was found of tumor substage with HER-2/neu expression. In the untreated group patients with tumors showing high HER-2/neu expression had a decreased survival rate (p = 0.044). Conclusions: High HER-2/neu expression is highly associated with exposure to hormone therapy and androgen independence. It may contribute to androgen independence in prostate cancer and identify patients with prostate cancer more likely to have disease progression, particularly those not exposed to previous hormone therapy.

Original languageEnglish
Pages (from-to)1514-1519
Number of pages6
JournalJournal of Urology
Volume166
Issue number4
StatePublished - Sep 27 2001
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Hormones
Therapeutics
Neoplasms
Group Psychotherapy
Disease Progression
Proto-Oncogenes
Neoplasm Grading
Prostatectomy
Prostate
Survival Rate
Membranes

Keywords

  • Androgens
  • Biological
  • Prostate
  • Prostatic neoplasms
  • Proto-oncogenes
  • Tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

HER-2/neu expression in prostate cancer : High level of expression associated with exposure to hormone therapy and androgen independent disease. / Shi, Yan; Brands, Frank H.; Chatterjee, Sunanda; Feng, An Chen; Groshen, Susan; Schewe, Jörg; Lieskovsky, Gary; Cote, Richard J.

In: Journal of Urology, Vol. 166, No. 4, 27.09.2001, p. 1514-1519.

Research output: Contribution to journalArticle

Shi, Y, Brands, FH, Chatterjee, S, Feng, AC, Groshen, S, Schewe, J, Lieskovsky, G & Cote, RJ 2001, 'HER-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease', Journal of Urology, vol. 166, no. 4, pp. 1514-1519.
Shi, Yan ; Brands, Frank H. ; Chatterjee, Sunanda ; Feng, An Chen ; Groshen, Susan ; Schewe, Jörg ; Lieskovsky, Gary ; Cote, Richard J. / HER-2/neu expression in prostate cancer : High level of expression associated with exposure to hormone therapy and androgen independent disease. In: Journal of Urology. 2001 ; Vol. 166, No. 4. pp. 1514-1519.
@article{cafa0b3864ea4c35ad87b5482f1568a3,
title = "HER-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease",
abstract = "Purpose: HER-2/neu is a proto-oncogene that encodes a transmembrane receptor belonging to the family of epidermal growth factor receptors. Increasing evidences indicates that HER-2/neu may contribute to hormone resistance in prostate cancer. We investigated HER-2/neu expression in primary, androgen dependent and advanced androgen independent prostate cancer, and its potential value as a marker of disease progression. Materials and Methods: Immunohistochemical testing was performed to investigate HER-2/ neu expression in 81 patients with prostate cancer, including 31 with pathological stage C disease treated with radical prostatectomy without preoperative androgen ablation therapy (untreated group), 30 with pathological stage C disease treated before surgery with androgen ablation therapy (treated group) and 20 with advanced androgen independent prostate cancer (androgen independent group). Tumors were classified based on the percent of tumor cells showing HER-2/neu membrane immunoreactivity as low (50{\%} or less) and high (50{\%} or greater) expression. Results: Of the 31 prostate tumors in the untreated group 9 (29{\%}) showed high HER-2/neu expression versus 15 of 30 (50{\%}) in the treated and 17 of 20 (85{\%}) in the androgen independent groups. The difference in HER-2/neu expression was significant in the untreated and androgen independent (p <0.001) and in the treated and androgen independent (p = 0.016) groups. There was a significant association of Gleason score with HER-2/neu expression in the untreated group (p = 0.038) but not in the treated group. No association was found of tumor substage with HER-2/neu expression. In the untreated group patients with tumors showing high HER-2/neu expression had a decreased survival rate (p = 0.044). Conclusions: High HER-2/neu expression is highly associated with exposure to hormone therapy and androgen independence. It may contribute to androgen independence in prostate cancer and identify patients with prostate cancer more likely to have disease progression, particularly those not exposed to previous hormone therapy.",
keywords = "Androgens, Biological, Prostate, Prostatic neoplasms, Proto-oncogenes, Tumor markers",
author = "Yan Shi and Brands, {Frank H.} and Sunanda Chatterjee and Feng, {An Chen} and Susan Groshen and J{\"o}rg Schewe and Gary Lieskovsky and Cote, {Richard J}",
year = "2001",
month = "9",
day = "27",
language = "English",
volume = "166",
pages = "1514--1519",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - HER-2/neu expression in prostate cancer

T2 - High level of expression associated with exposure to hormone therapy and androgen independent disease

AU - Shi, Yan

AU - Brands, Frank H.

AU - Chatterjee, Sunanda

AU - Feng, An Chen

AU - Groshen, Susan

AU - Schewe, Jörg

AU - Lieskovsky, Gary

AU - Cote, Richard J

PY - 2001/9/27

Y1 - 2001/9/27

N2 - Purpose: HER-2/neu is a proto-oncogene that encodes a transmembrane receptor belonging to the family of epidermal growth factor receptors. Increasing evidences indicates that HER-2/neu may contribute to hormone resistance in prostate cancer. We investigated HER-2/neu expression in primary, androgen dependent and advanced androgen independent prostate cancer, and its potential value as a marker of disease progression. Materials and Methods: Immunohistochemical testing was performed to investigate HER-2/ neu expression in 81 patients with prostate cancer, including 31 with pathological stage C disease treated with radical prostatectomy without preoperative androgen ablation therapy (untreated group), 30 with pathological stage C disease treated before surgery with androgen ablation therapy (treated group) and 20 with advanced androgen independent prostate cancer (androgen independent group). Tumors were classified based on the percent of tumor cells showing HER-2/neu membrane immunoreactivity as low (50% or less) and high (50% or greater) expression. Results: Of the 31 prostate tumors in the untreated group 9 (29%) showed high HER-2/neu expression versus 15 of 30 (50%) in the treated and 17 of 20 (85%) in the androgen independent groups. The difference in HER-2/neu expression was significant in the untreated and androgen independent (p <0.001) and in the treated and androgen independent (p = 0.016) groups. There was a significant association of Gleason score with HER-2/neu expression in the untreated group (p = 0.038) but not in the treated group. No association was found of tumor substage with HER-2/neu expression. In the untreated group patients with tumors showing high HER-2/neu expression had a decreased survival rate (p = 0.044). Conclusions: High HER-2/neu expression is highly associated with exposure to hormone therapy and androgen independence. It may contribute to androgen independence in prostate cancer and identify patients with prostate cancer more likely to have disease progression, particularly those not exposed to previous hormone therapy.

AB - Purpose: HER-2/neu is a proto-oncogene that encodes a transmembrane receptor belonging to the family of epidermal growth factor receptors. Increasing evidences indicates that HER-2/neu may contribute to hormone resistance in prostate cancer. We investigated HER-2/neu expression in primary, androgen dependent and advanced androgen independent prostate cancer, and its potential value as a marker of disease progression. Materials and Methods: Immunohistochemical testing was performed to investigate HER-2/ neu expression in 81 patients with prostate cancer, including 31 with pathological stage C disease treated with radical prostatectomy without preoperative androgen ablation therapy (untreated group), 30 with pathological stage C disease treated before surgery with androgen ablation therapy (treated group) and 20 with advanced androgen independent prostate cancer (androgen independent group). Tumors were classified based on the percent of tumor cells showing HER-2/neu membrane immunoreactivity as low (50% or less) and high (50% or greater) expression. Results: Of the 31 prostate tumors in the untreated group 9 (29%) showed high HER-2/neu expression versus 15 of 30 (50%) in the treated and 17 of 20 (85%) in the androgen independent groups. The difference in HER-2/neu expression was significant in the untreated and androgen independent (p <0.001) and in the treated and androgen independent (p = 0.016) groups. There was a significant association of Gleason score with HER-2/neu expression in the untreated group (p = 0.038) but not in the treated group. No association was found of tumor substage with HER-2/neu expression. In the untreated group patients with tumors showing high HER-2/neu expression had a decreased survival rate (p = 0.044). Conclusions: High HER-2/neu expression is highly associated with exposure to hormone therapy and androgen independence. It may contribute to androgen independence in prostate cancer and identify patients with prostate cancer more likely to have disease progression, particularly those not exposed to previous hormone therapy.

KW - Androgens

KW - Biological

KW - Prostate

KW - Prostatic neoplasms

KW - Proto-oncogenes

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0034833701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034833701&partnerID=8YFLogxK

M3 - Article

VL - 166

SP - 1514

EP - 1519

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -